Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy.

Studied

A narrative review examined whether tirzepatide changes absorption of oral progestogens used for gynaecologic conditions or menopausal hormone therapy.

Who / model

The review searched literature through February 2026 and found one pharmacokinetic study using a combined oral contraceptive. Its participant count is not stated in the abstract.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

In that single-dose study, peak hormone concentrations fell 55–66%, total exposure fell 20–23%, and peaks occurred 2.5–4.5 hours later.

Limits

Lower peak concentrations do not establish reduced effectiveness. Equivalent data for therapeutic or menopausal progestogens were absent, and clinical effects remain untested.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary